Supernus Pharma (SUPN) Tops Q2 EPS by 14c, Revenues Miss; Offers FY18 Revenue Outlook Below Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
| SUPERNUS PHARM (NASDAQ: SUPN) | Delayed: 41.84 +0.76 (1.85%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $41.08 | 52 Week High | $26.84 | |||
| Open | $44.24 | 52 Week Low | $9.51 | |||
| Day High | $44.31 | P/E | N/A | |||
| Day Low | $40.75 | EPS | $-2.62 | |||
| Volume | 1,885,190 | |||||
